AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS - Takeaways - MDSpire
From the Journals

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transpla...

  • By

  • Lisa Astor

  • May 8, 2026

  • 8 min

Share

  • 1

    AlloHeme tool shows enhanced sensitivity in relapse prediction post-HCT.

  • 2

    Study involved 285 patients with AML and MDS monitored over 2 years.

  • 3

    Achieved 85% sensitivity and 92% specificity.

  • 4

    Detected relapse a median of 41 days prior to clinical signs.

  • 5

    More effective than standard donor engraftment testing.

  • 6

    Potential for earlier interventions indicated by positive test results.

  • 7

    Compliance with the testing schedule impacted results.

Original Source(s)

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

  • by Lisa Astor

  • May 8, 2026

Related Content

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book.    

  • by ASCO

  • May 8, 2026

  • 2 min
National Academy of Medicine Recognizes 100 Newly Elected Members

Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.